63 results about "Recombinant antigen" patented technology

This invention discloses an ANXA1 recombinant antigen, its preparation method, and its applications, belonging to the field of biodetection technology. The ANXA1 recombinant antigen of this invention is based on the wild-type ANXA1 protein shown in SEQ ID NO.1, obtained by deleting its first epitope-masking region, thus making the epitope more easily exposed. Verification has shown that, compared to the full-length ANXA1 antigen, the ANXA1 recombinant antigen of this invention has improved sensitivity in early lung cancer detection, and its detection performance is significantly superior to commercially available ANXA1 recombinant antigens. Therefore, the ANXA1 recombinant antigen of this invention provides a new approach for the early auxiliary diagnosis of lung cancer.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The application provides a recombinant antigen protein p22 of an African swine fever virus, a monoclonal antibody and application. The application provides a recombinant antigen protein of an African swine fever virus. The application provides an antibody or antigen binding fragment thereof of the recombinant antigen protein of the African swine fever virus. The application also provides a hybridoma cell. The application also provides a rapid detection test paper card of the African swine fever antibody. The recombinant antigen protein of the African swine fever virus provided by the application has higher affinity to the African swine fever antibody, higher specificity and better stability, and can be used for rapid and accurate detection of the African swine fever virus.

The invention discloses a MAGE A1 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the MAGE A1 recombinant antigen disclosed by the invention is as shown in SEQ ID NO. 1. Through verification, compared with a full-length MAGE A1 antigen, the MAGE A1 recombinant antigen disclosed by the invention has the advantage that the sensitivity of the MAGE A1 recombinant antigen in early lung cancer detection is improved. Therefore, the MAGE A1 recombinant antigen provides a new way for early auxiliary diagnosis of lung cancer.

This invention relates to an ELISA detection kit for porcine reproductive and respiratory syndrome virus (PRRSV) based on M-GP5 recombinant protein, and belongs to the field of ELISA detection technology. The kit includes recombinant (M-GP5) antigen protein, an ELISA plate, blocking buffer, primary antibody dilution buffer, enzyme-labeled secondary antibody, secondary antibody dilution buffer, chromogenic solution, stop solution, negative serum, and positive serum. It features high sensitivity, high specificity, and good stability, and can accurately detect PRSV antibodies.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

The invention discloses a neutralizing antibody with an AQP3 channel blocking function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The neutralizing antibody can be specifically combined with an extracellular domain of AQP3, after combination, a water channel and a small molecule transport function of the AQP3 are blocked through steric hindrance and conformation change, and meanwhile, antigen combination specificity is reserved. The preparation method is realized through'recombinant antigen-immunization-B cell screening culture-recombinant antibody expression and affinity purification-ELISA detection ', and the functions of the antibody are ensured. The antibody can be efficiently combined with AQP3 positive cells, is strong in targeting property and high in specificity (the serum titer reaches 1: 1024 * 10, and the purified antibody titer is greater than or equal to 1: 128 * 10), and can be independently used or combined with a nano-carrier for treating related diseases, so that the technical bottleneck that a common AQP3 antibody can only be combined and cannot efficiently play a blocking role is solved.

The application provides a combined detection test strip for dengue virus, Zika virus antigen and antibody and a preparation method thereof; the combined detection test strip of the application adopts a multi-site recombinant antigen marking or multi-site recombinant antibody coating form for the combined detection test strip for dengue virus NS1 antigen and dengue virus IgG / IgM antibody, thereby improving the sensitivity of the reagent; the application also overcomes the problems of poor specificity and release residue of the latex microspheres by optimizing a blocking solution; color latex microspheres are used as the markers, the target is more intuitively detected according to the color of the lines, clinical result interpretation is facilitated, the accuracy of dengue virus infection and Zika virus infection is improved, dengue virus NS1, Zika virus NS1 antigen, dengue virus IgG / IgM antibody detection and Zika virus IgG / IgM antibody can be simultaneously detected; moreover, the application is convenient to carry and easy to operate, is convenient for on-site instant detection and can be used for large-scale preliminary screening.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application discloses a kind of modular serum-free cell culture medium and its application, belong to biomedical technology field.The culture medium includes: epidermal growth factor, recombinant insulin, cholesterol-phospholipid nanoparticles, beta-mercaptoethanol, pluronic F-68, glucose / glutamine, trace element mixed solution.The modular serum-free cell culture medium provided by the application can not only meet the large-scale culture of stem cells, but also be used for the industrial production of in vitro diagnostic reagent raw materials such as recombinant antigen, viral vector, recombinant protein and monoclonal antibody, with wide cell adaptability, low production cost, significant economy, stable process, and strict requirements of FDA / EMA for biological products.

The invention discloses a latex microsphere identification and detection test strip for detecting a bovine leukemia virus antibody and application thereof. The test strip comprises a chromatography membrane, a water absorption pad, a latex labeling pad and a sample pad which are adhered to a PVC (polyvinyl chloride) bottom plate, a quality control line and a detection line are arranged on the chromatography membrane; the detection line is formed by spraying a BLV gp51 recombinant antigen protein, and the quality control line is formed by spraying a goat anti-chicken IgY antibody; the latex labeling pad is sprayed with BLV gp51 recombinant antigen protein and a chicken IgY antibody which are combined with the red latex microspheres. According to the invention, the BLV gp51 prokaryotic expression antigen and the red latex microsphere immunochromatography technology are combined for the first time, a double-antigen sandwich detection system suitable for the field is established, the dependence of traditional ELISA on equipment and operation environment is broken through, and the high specificity (gt; according to the present invention, the rapid interpretation within 15 min is achieved while the detection limit is 1: 256, such that the reliable and convenient technical tool is provided for the basic level prevention and control of the BLV.

This invention discloses a multi-epitope virus-like particle antigen (VLP) of type O foot-and-mouth disease virus (FMDV), its preparation method, and its application. The type O FMDV VLP antigen is a recombinant antigen protein formed by sequentially tandemly connecting the antigenic epitopes of five representative strains of type O FMDV topotypes—O / Tibet / CHA / 99, O / Mya98 / BY / 2010, O / HN / CHA / 93, O / XJPS / CHA / 2017, and Cathay—with the SpyCather and bacteriophage AP205 genes, and then tandemly connecting them with the epitopes of the first four strains. This recombinant protein can self-assemble into a VLP antigen. Immunological experiments show that this VLP antigen has good antigenicity, and its antigenic reactivity with type O FMDV is not significantly different, making it a viable alternative to inactivated FMDV antigens in detection methods. Vaccines prepared using this VLP antigen not only induce high levels of protective antibodies but also protect immunized animals against viral challenge. Furthermore, it is not limited by animal species and provides immune protection against type O foot-and-mouth disease in pigs, cattle, and sheep.

The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.

The invention belongs to the technical field of biological detection, and particularly relates to an immunodetection reagent for blood virus screening and a preparation method of the immunodetection reagent. The immunodetection reagent comprises the following raw materials in parts by weight: 100 parts of a capture reagent, 300 parts of a sealing agent, 300 parts of a cracking agent, 1 part of an HCV recombinant antigen, 1 part of an anti-HCVcAg monoclonal antibody, 0.2-0.6 part of hydroxymethylcoumarin, 10 parts of BSA, 2-6 parts of glutaric anhydride, 4-8 parts of TEOS and 100 parts of a PBS buffer solution. According to the present invention, the silica microsphere with the HCV recombinant antigen and the anti-HCVcAg monoclonal antibody coupled on the surface and the hydroxymethylcoumarin signal molecule loaded inside is constructed, and the HCV antigen and the HCV antibody in the serum are specifically recognized so as to achieve the efficient diagnosis and detection of the HCV infection in the whole cycle;

This invention discloses a kit for the quantitative detection of C-reactive protein (CRP) in giant pandas and its application, belonging to the field of biodetection technology. The kit disclosed in this invention comprises reagent R2 with the following concentrations: 50 mM PBS pH 7.5, Tween-20 6 ml / L, 270 nm polystyrene carboxylated latex 2.5 g / L, sucrose 30 g / L, BSA 10 g / L, rabbit anti-giant panda CRP polyclonal antibody 6.75 mg / L, and preservative 0.5 ml / L. The rabbit anti-giant panda CRP polyclonal antibody is obtained by immunizing giant white rabbits with the recombinant antigen expressed by the sequence shown in SEQ ID NO. 4. This invention provides a highly efficient, simple, low-cost, and scalable detection method.

The invention discloses a kit for quantitatively detecting panda C-reactive protein and application of the kit, and belongs to the technical field of biological detection. The invention discloses a kit for quantitatively detecting panda C reactive protein. A reagent R2 is prepared from the following components in concentration: 50 mM PBS (Phosphate Buffer Solution) with pH (Potential of Hydrogen) of 7.5, 6 ml / L of tween-20, 2.5 g / L of 270 nm polystyrene carboxyl latex, 30 g / L of sucrose, 10 g / L of BSA (Bovine Serum Albumin), 6.75 mg / L of rabbit anti-panda CRP (C reactive protein) polyclonal antibody and 0.5 ml / L of preservative; the rabbit anti-panda CRP polyclonal antibody is obtained by immunizing a rabbit with a recombinant antigen expressed by the sequence as shown in SEQ ID NO.4. The invention provides a detection scheme which is efficient, simple, convenient, low in cost and capable of being popularized on a large scale.

This invention relates to the field of immunodiagnostics and provides recombinant HIV antigens for HIV antibody detection. Specifically, it concerns recombinant HIV antigens, nucleic acid molecules, expression vectors, host cells, reagents, kits, and their use. When recombinant HIV antigen proteins are used as the labeling end, the marker activity of the recombinant HIV antigen can be significantly improved, and nonspecific immunobinding activity can be reduced, thereby increasing sensitivity.

The application discloses a plant-expressed varicella-zoster virus gB recombinant antigen and a preparation method, product and application thereof, and belongs to the technical field of plant molecular biology and vaccine engineering. The technical problems to be solved are that the existing VZV gB protein has low heterologous expression, poor stability and insufficient antigen activity; the existing VZV vaccine has high production cost, is difficult to popularize and has a single antigen with an immune escape risk; and the plant expression system is not mature in VZV gB antigen production, and lacks a complete preparation scheme and related products. The technical solution is that the natural VZV gB protein is modified, a furin protease cleavage site is knocked out, and a H527P mutation is introduced, related nucleic acid molecules, vectors and plant source cells are constructed, high-activity antigens are obtained through culture and purification, and the high-activity antigens are applied to the preparation of VZV drugs / vaccines, and have the advantages of low cost, high safety and strong immunogenicity.

The invention discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence derived from a non-structural protein NS7 of FCV with a coding sequence of a SpyTag peptide fragment through a coding sequence of a linker, and cloning to a baculovirus transfer vector to obtain a recombinant plasmid; and finally, integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. According to the invention, NS7 is selected as a core immunogen to guide an immune system to generate high cellular immune response, so that the defect of an existing vaccine in removing viruses in cells is overcome; meanwhile, T cell epitopes with specificity are selected from the sequence of NS7 as immunogens, so that the variability of antigens among different strains and immune escape caused by virus antigen drift can be avoided, and wider-spectrum protection is provided.

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

The present invention concerns genetically modified immune cell, which (a) overexpresses p21 compared to a corresponding non-genetically modified immune cell, (b) expresses at its surface a recombinant antigen binding domain, and (c) is a monocyte, a macrophage, or a dendritic cell, as well as methods for producing them, pharmaceutical compositions comprising them, and their use as a medicament, in particular in the treatment of a subject suffering from a cell proliferative disorder, in particular cancer.

The invention relates to the field of toxoplasma gondii detection, and discloses a toxoplasma gondii IgM antibody detection test strip, which comprises a substrate, a sample loading pad, a colloidal gold adsorption pad marked with a C line, a colloidal gold adsorption pad marked with a T line, and a water absorption pad, a sample loading pad, a colloidal gold adsorption pad marked with a C line, a colloidal gold adsorption pad marked with a T line, a nitrocellulose membrane and a water absorption pad are sequentially arranged on the substrate along the liquid chromatography direction; the solid-phase colloidal gold T line is labeled with a TOX recombinant antigen, and the solid-phase colloidal gold C line is labeled with a mouse monoclonal antibody; the nitrocellulose membrane is sequentially coated with a detection line and a quality control line; the detection line is coated with an anti-human IgM chain monoclonal antibody, and the quality control line is coated with an anti-mouse IgG polyclonal antibody; the test strip has the technical advantages of high sensitivity and high specificity, few types of raw materials are used, the use amount is low, the production cost is effectively controlled, the quantity of samples required for detection is extremely small, the efficiency is high, special instruments are not needed, direct judgment can be carried out through naked eyes, and the operation is more convenient and efficient.

The present application relates to the technical field of in vitro diagnosis, in particular to a composition and a kit, and provides a magnetic microparticle chemiluminescence kit for detecting coxsackievirus A10 IgM, and further provides a recombinant antigen EV71, CA16 and CA6 combination for blocking cross infection and improving the specific detection rate of CA10, which comprises magnetic particles coated with mouse anti-human IgM monoclonal antibody, horseradish peroxidase-labeled coxsackievirus A10 antigen, horseradish peroxidase-labeled coxsackievirus EV71 type, A16 type and A6 type combined blocking antigen. The kit provided by the present application has high sensitivity and specificity, and can distinguish EV71 type, CA16 type and CA6 infection cross in hand-foot-mouth disease, specifically detect A10 pathogens, and has high repeatability and simple operation.

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to fusion protein and nanoparticles of porcine reproductive and respiratory syndrome virus recombinant epitopes and application of the fusion protein and the nanoparticles. A GP3 protein antigen epitope, a GP4 protein antigen epitope, a GP5 protein antigen epitope and an M protein antigen epitope are recombined, the obtained recombinant protein is closely related to protective immunity of the PRRSV, a strong humoral immune response aiming at the PRRSV can be generated after piglets are immunized, and a good protection effect is generated on infection of the PRRSV. The fusion protein is connected with the beta-cyclopeptide, and the beta-cyclopeptide serving as a nano skeleton can spontaneously form 24-surface nanoparticles, so that the antigen can be effectively presented, and the immune effect of the vaccine is promoted. Furthermore, the N terminal of the beta cyclopeptide is connected with an OX40L protein, and the OX40L protein belongs to a tumor necrosis factor ligand superfamily, so that the cellular immune effect can be further improved.

The application provides two monoclonal antibodies XJ16 and XJ23 against a recombinant antigen protein membrane surface antigen SAG1 protein of Toxoplasma gondii, the antibodies can specifically recognize Toxoplasma gondii at various stages, have the characteristics of high sensitivity and wide recognition range, can detect Toxoplasma gondii infection at various stages, can be used for detecting the existence and content of Toxoplasma gondii in samples, lays a foundation for exploring Toxoplasma gondii, and provides a new exploration idea for exploring the mechanism of rapid and slow Toxoplasma gondii transformation and then developing new prevention and treatment strategies.

The invention provides a preparation method of an intestinal fatty acid binding protein IFABP antigen, which comprises the following steps: S1, designing a mature peptide into a signal peptide-6 * His-linker peptide-IFABP-linker peptide-IFABP-YINK-containing signal peptide dimer protein based on a gene sequence of an NCBI (National Center of Biotechnology Information) login number NP000125.2 encoding human IFABP mature peptide, and performing codon optimization on an amino acid sequence of the signal peptide-6 * His-linker peptide-IFABP-linker peptide-IFABP-YINK to obtain a nucleic acid sequence; s2, cloning the optimized gene into a eukaryotic expression vector, and constructing a recombinant expression plasmid; and S3, transfecting the recombinant plasmid into a mammalian cell 293F, carrying out cell culture after transfection, and purifying to obtain the IFABP antigen. According to the preparation method, the high-purity and high-activity IFABP recombinant antigen can be efficiently obtained on a large scale, and then the high-performance anti-IFABP monoclonal antibody is obtained.

The invention provides a composite vaccine adjuvant based on ergothioneine-sulfhydrylated polypeptide and a vaccine composition and application thereof, and belongs to the crossing field of biotechnology and medicine (including veterinary use). The composite vaccine adjuvant comprises a component A and a component B, wherein the component A comprises the following components in percentage by weight: 0.5%-5.0% of L-ergothioneine, 0.3%-2.0% of (Gly-SH) n oligopeptide, 2.0%-8.0% of aluminum hydroxide and / or aluminum phosphate, 1.0%-3.0% of a targeting carrier, 5.5%-13.0% of a freeze-drying protective additive and the balance of a buffer solution; the component B is CpG ODN, and the final concentration of the component B is 10-25 mu g / mL. The composite vaccine adjuvant system integrates sulfhydrylation modification enhanced combination and multi-component synergistic immunization, can be used for inducing balanced Th1 / Th2 immune response of mammals (including human, pigs, cattle and the like) and birds (chicken, ducks and the like) to intracellular / extracellular pathogens, and can be adapted to subunit vaccines, inactivated vaccines, recombinant antigen vaccines and combined vaccines; meanwhile, healthy groups and immunosuppressive groups (young, stress substance and immunodeficient groups) are compatible.

Proposed herein are a polypeptide including a SARS-CoV-2 universal antigen amino acid sequences, and a polynucleotide encoding the polypeptide. Also proposed herein are a vaccine composition for preventing SARS-CoV-2 infection, and a pharmaceutical composition for preventing or treating SARS-CoV-2 infection, wherein the vaccine and pharmaceutical compositions contain the polypeptide or polynucleotide as an active ingredient. The present invention provides a universal antigen polypeptide capable of responding not only to wild-type SARS-CoV-2 and currently circulating SARS-CoV-2 variants, but also to hypothetical SARS-CoV-2 variants, as well as a polynucleotide encoding the same. In addition, the present invention provides a SARS-CoV-2 universal antigen polypeptide with enhanced structural stability through amino acid substitutions at specific positions of the universal antigen polypeptide, and a polynucleotide encoding the same. Furthermore, the present invention provides a vaccine composition and a pharmaceutical composition comprising the SARS-CoV-2 universal antigen polypeptide or the polynucleotide as an active ingredient.